• Entera Bio posted a net loss of $7.3 million, or $0.14 per share, for the quarter ended June 30, 2026, versus $2.7 million, or $0.06 per share, a year earlier.
• R&D expense more than doubled to $3.2 million, due to EB613 Phase 3 preparations and OPKO-collaboration activities; G&A rose 27.27% to $1.4 million.
• Cash and cash equivalents were $11.3 million, restricted cash totaled $7.1 million; pro forma cash after the July private placement expected to fund operations into 2030.
• FDA accepted a 12-month registrational Phase 3 plan for EB613 in about 750 patients, with study start late 2026 and topline data expected in 2H 2028.
• Miranda Toledano called the $275 million BVF-led private placement “transformational,” funding EB613 through anticipated NDA submission and advancing EB612 toward a 1H 2027 IND.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entera Bio Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608071605PRIMZONEFULLFEED9805988) on August 07, 2026, and is solely responsible for the information contained therein.